LIQID Medical develops lifelong implants for glaucoma treatment that utilize the retrolaminar drainage pathway, providing a novel approach to managing this leading cause of irreversible blindness. Their QMAX and QFLOW devices aim to enhance surgical efficiency and patient outcomes by addressing the limitations of traditional drainage methods.
Funding
$2.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Glaucoma, a leading cause of irreversible blindness, often requires surgical intervention when medication and laser treatments fail to adequately lower intraocular pressure (IOP). Traditional glaucoma drainage devices can suffer from complications related to the subconjunctival drainage pathway, such as bleb formation and subsequent failure.
Solution
LIQID Medical is developing lifelong implants that utilize the retrolaminar drainage pathway to manage glaucoma. Their QMAX device is designed as a highly effective glaucoma solution that bypasses the traditional subconjunctival drainage pathway. The QFLOW device harnesses the traditional fluid drainage pathway, but with an innovative design intended to reduce surgical operating times, costs, and complications. Both devices aim to improve surgical efficiency and patient outcomes by providing effective, long-term IOP control.
Target Audience
The primary target audience includes glaucoma surgeons and patients with severe or refractory glaucoma requiring surgical intervention for IOP management.
Features
- QMAX implant utilizes the retrolaminar drainage pathway, avoiding subconjunctival complications.
- QFLOW implant employs an innovative design to optimize traditional fluid drainage.
- Devices are intended to provide long-term IOP control, reducing the need for repeat surgeries.